D-1235-2020 Class II Terminated

Recalled by Aurobindo Pharma USA Inc. — East Windsor, NJ

FDA drug recall D-1235-2020 was initiated by Aurobindo Pharma USA Inc. on Mar 18, 2020 and is designated Class II. Reason for recall: CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed The recall status is terminated (terminated Mar 25, 2024). Affected quantity: 56208 units.

Recall details

Product Type
Drugs
Report Date
Apr 22, 2020
Initiation Date
Mar 18, 2020
Termination Date
Mar 25, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
56208 units

Product description

Mirtazapine Tablets, USP 15mg, 30-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 13107-031-34

Reason for recall

CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed

Distribution pattern

Nationwide within the United States

Code information

Lot #: 031180028A, Exp. Date 03/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1235-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1235-2020. Report a data issue: hello@regdatalab.com.